Cargando…

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy. Patients and Methods. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodrigo, J. A., Hicks, L. K., Cheung, M. C., Song, K. W., Ezzat, H., Leger, C. S., Boro, J., Montaner, J. S. G., Harris, M., Leitch, H. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235428/ https://www.ncbi.nlm.nih.gov/pubmed/22190945 http://dx.doi.org/10.1155/2012/735392

Ejemplares similares

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
por: Chen, Meiting, et al.
Publicado: (2021)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports
por: Yang, Xiao-Yan, et al.
Publicado: (2017)

A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC
por: Bemis, Thomas, et al.
Publicado: (2019)

Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression
por: Noy, Ariela, et al.
Publicado: (2012)

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()
por: McMillan, A.K., et al.
Publicado: (2020)

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
por: Ambler, Kimberley L. S., et al.
Publicado: (2012)

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009)

Neurodegeneration in the HAART era
por: Brew, Bruce J
Publicado: (2010)

Effectiveness and Safety of a Prolonged Hemodynamic Support by the IVAC2L System in Healthy and Cardiogenic Shock Pigs
por: Delmas, Clément, et al.
Publicado: (2022)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Case Report First-in-Man Method Description: Left Ventricular Unloading With iVAC2L During Veno-Arterial Extracorporeal Membrane Oxygenation: From Veno-Arterial Extracorporeal Membrane Oxygenation to ECMELLA to EC-iVAC®
por: Tschöpe, Carsten, et al.
Publicado: (2020)

Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy?
por: Vasudevan, Janani, et al.
Publicado: (2012)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Human Polyomavirus-Associated Cerebral Disorders in the Post-HAART Era
por: Cedeno-Laurent, Filiberto, et al.
Publicado: (2011)

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
por: Lu, Xiaoxuan, et al.
Publicado: (2022)

Nephrotoxicity of HAART
por: Kalyesubula, Robert, et al.
Publicado: (2011)

The value and implementation of routine ophthalmic examination in the era of HAART
por: Li, Wangting, et al.
Publicado: (2020)

HAART and the liver: friend or foe?
por: Pineda, JA, et al.
Publicado: (2010)

Ophthalmic manifestations of human immunodeficiency virus infection: Pre- highly active antiretroviral chemotherapy (HAART) and post- HAART era
por: Sinha, Rajesh, et al.
Publicado: (2008)

Pattern of cancer risk in persons with AIDS in Italy in the HAART era
por: Dal Maso, L, et al.
Publicado: (2009)

Burkitt lymphoma in Papua, New Guinea.
por: Booth, K., et al.
Publicado: (1967)

Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
por: Onigbogi, MO, et al.
Publicado: (2010)

Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
por: Geerts, Paulus A. F., et al.
Publicado: (2023)

Survival of Burkitt's Lymphoma Patients in Ghana
por: Wosornu, J. L., et al.
Publicado: (1971)

Emergency department utilization by HIV-positive adults in the HAART era
por: Venkat, Arvind, et al.
Publicado: (2008)

The Impact of HIV on Maternal Morbidity in the Pre-HAART Era in Uganda
por: Nuwagaba-Biribonwoha, Harriet, et al.
Publicado: (2012)

Intensive Care Usage by HIV-Positive Patients in the HAART Era
por: Turtle, L., et al.
Publicado: (2011)

AIDS and the pancreas in the HAART era: a cross sectional study
por: Barbosa, Alexandre G, et al.
Publicado: (2013)

Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era
por: Iordache, Laura, et al.
Publicado: (2017)

Cytology and Histochemistry of the Burkitt Lymphoma
por: Wright, D. H.
Publicado: (1963)

Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada
por: Lima, Viviane D., et al.
Publicado: (2010)

Malignancies in human immunodeficiency virus infected patients in India: Initial experience in the HAART era
por: Sharma, Surendra K., et al.
Publicado: (2015)

Educational Case: Burkitt Lymphoma
por: Alexander, Caitlin J., et al.
Publicado: (2019)

Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab
por: Huang, Shuang, et al.
Publicado: (2021)

Excretion of Immunoglobulins in Burkitt's Lymphoma
por: McFarlane, H., et al.
Publicado: (1970)

Smoking and Predictors of Pneumonia Among HIV-Infected Patients Receiving Care in the HAART Era
por: Murdoch, David M, et al.
Publicado: (2008)

Metropolitan Social Environments and Pre-HAART/HAART Era Changes in Mortality Rates (per 10,000 Adult Residents) among Injection Drug Users Living with AIDS
por: Friedman, Samuel R., et al.
Publicado: (2013)

HAART rollout in the new fiscal and economic environment
por: Moatti, J
Publicado: (2012)

Respiratory Symptoms and Airway Obstruction in HIV-Infected Subjects in the HAART Era
por: George, M. Patricia, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_a109npmggljfau1quh40j90lqe